Molecular Partners (NASDAQ:MOLN) Stock Price Down 5.9%

Molecular Partners AG (NASDAQ:MOLN)’s share price fell 5.9% during trading on Thursday . The company traded as low as $3.65 and last traded at $3.65. 2,068 shares changed hands during trading, a decline of 85% from the average session volume of 13,668 shares. The stock had previously closed at $3.88.

Molecular Partners Price Performance

The business has a fifty day simple moving average of $4.06 and a two-hundred day simple moving average of $4.25.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.68) earnings per share for the quarter. The business had revenue of $1.17 million during the quarter. Molecular Partners had a negative return on equity of 31.10% and a negative net margin of 885.11%. On average, equities research analysts forecast that Molecular Partners AG will post -2.22 EPS for the current year.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.